Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide avp V 2-receptor antagonist: Results of single- and multiple-dose studies in healthy Japanese male volunteers

Cardiovascular Drugs and Therapy

Volumn 25, Issue SUPPL. 1, 2011, Pages

  Kim, Seong Ryul ^a   Hasunuma, Tomoko ^b   Sato, Osamu ^a   Okada, Tadashi ^a   Kondo, Mitsuhiro ^a   Azuma, Junichi ^c  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Aquaretic; Arginine vasopressin; Pharmacodynamics; Pharmacokinetics; Tolvaptan

Indexed keywords

PLACEBO; TOLVAPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD OSMOLARITY; BRADYCARDIA; CONTROLLED STUDY; DIARRHEA; DIURETIC ACTIVITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPONATREMIA; JAPANESE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SINUS ARREST; SODIUM BLOOD LEVEL; TACHYCARDIA; THIRST; URIC ACID BLOOD LEVEL; URINE OSMOLALITY; URINE VOLUME;

ADULT; AREA UNDER CURVE; ARGININE VASOPRESSIN; ASIAN CONTINENTAL ANCESTRY GROUP; BENZAZEPINES; CROSS-OVER STUDIES; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FOOD-DRUG INTERACTIONS; HUMANS; MALE; POTASSIUM; RECEPTORS, VASOPRESSIN; SODIUM; YOUNG ADULT;

EID: 83655198303     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6299-3     Document Type: Article

References (16)

1. RW Schrier T Berl RJ Anderson 1979 Osmotic and nonosmotic control of vasopressin release Am J Physiol 236 F321 32 373467 1:CAS:528:DyaE1MXitVSqtbs%3D
2. Rivera-Santos A, Star RA. Sodium: volume depletion and hyponatremia. In: Seldin D, Giebisch G, editors. Diuretic agents: clinical physiology and pharmacology. San Diego: Academic Press Inc; 1997. p. 559-69.
3. Palmer BF. Potassium disturbances associated with the use of diuretics. In: Seldin D, Giebisch G, editors. Diuretic agents: clinical physiology and pharmacology. San Diego: Academic Press Inc; 1997. p. 571-83.
4. CR Lee ML Watkins JH Pattetson, et al. 2003 Vasopressin: a new target for the treatment of heart failure Am Heart J 146 9 18 12851603 10.1016/S0002-8703(02)94708-3 1:CAS:528:DC%2BD3sXltF2ju7w%3D (Pubitemid 36851295)
5. A Greenberg JG Verballs 2006 Vasopressin receptor antagonists Kidney Int 69 2124 30 16672911 10.1038/sj.ki.5000432 1:CAS:528:DC%2BD28XlsVert7k%3D (Pubitemid 43882098)
6. Y Yamamura S Nakamura S Itoh, et al. 1998 OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats J Pharmacol Exp Ther 287 860 7 9864265 1:CAS:528:DyaK1MXjvVShsw%3D%3D (Pubitemid 29131593)
7. T Hirano Y Yamamura S Nakamura T Onogawa T Mori 2000 Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats J Pharmacol Exp Ther 292 288 94 10604960 1:CAS:528:DC%2BD3cXhslGktg%3D%3D (Pubitemid 30026383)
8. SE Shoaf Z Wang P Bricmont S Mallikaarjun 2007 Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects J Clin Pharmacol 47 1498 507 17925589 10.1177/0091270007307877 1:CAS:528:DC%2BD2sXhsVyjtr%2FO (Pubitemid 350115300)
9. Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Jusko WJ, Schentag JJ, editors. Applied pharmacokinetics: principles of therapeutic drug monitoring, vol. 2. 3rd ed. Vancouver: Applied Therapeutics; 1992. p. 1-43.
10. K Gough M Hutchison O Keene, et al. 1995 Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party Drug Inf J 29 1039 48
11. SE Shoaf MV Elizari Z Wang, et al. 2005 Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias J Cardiovasc Pharmacol Ther 10 165 71 16211205 10.1177/ 107424840501000304 1:CAS:528:DC%2BD2MXhtFGrsbzM (Pubitemid 41376974)
12. SP Myrand K Sekiguchi MZ Man, et al. 2008 Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations Clin Pharmacol Ther 84 347 61 18231117 10.1038/sj.clpt.6100482 1:CAS:528:DC%2BD1cXhtVShtr%2FK
13. L Dodion Y Ambroes N Lameire 1986 A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemide and furosemide, in normal volunteers Eur J Clin Pharmacol 31 21 7 3780837 10.1007/BF00541463 1:CAS:528:DyaL2sXktlOmsg%3D%3D
14. SE Shoaf SL Bramer P Bricmont CA Zimmer 2007 Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide J Cardiovasc Pharmacol 50 213 22 17703139 10.1097/FJC.0b013e318074f934 1:CAS:528:DC%2BD2sXptFemtro%3D (Pubitemid 47267748)
15. Schrier RW. The patient with hyponatremia or hypernatremia. In: Schrier RW, editor. Manual of nephrology. 4th ed. Boston: Little, Brown & Co; 1995. p. 20-36.
16. Zeidel ML. Special diuretics. In: Seldin D, Giebisch G, editors. Diuretic agents: clinical physiology and pharmacology. San Diego: Academic Press Inc; 1997. p. 113-34.